Compare LMB & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMB | PRME |
|---|---|---|
| Founded | 1901 | 2019 |
| Country | United States | United States |
| Employees | 1400 | N/A |
| Industry | Engineering & Construction | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 579.3M | 553.2M |
| IPO Year | 2014 | 2022 |
| Metric | LMB | PRME |
|---|---|---|
| Price | $50.32 | $3.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $116.67 | $7.56 |
| AVG Volume (30 Days) | 415.9K | ★ 2.6M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.68 | 18.18 |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $646,804,000.00 | $4,632,000.00 |
| Revenue This Year | $15.96 | $7.06 |
| Revenue Next Year | $5.90 | $47.01 |
| P/E Ratio | $64.22 | ★ N/A |
| Revenue Growth | 24.68 | ★ 55.28 |
| 52 Week Low | $40.74 | $2.67 |
| 52 Week High | $114.95 | $6.94 |
| Indicator | LMB | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 45.30 | 47.08 |
| Support Level | $40.74 | $3.16 |
| Resistance Level | $84.79 | $3.69 |
| Average True Range (ATR) | 1.87 | 0.23 |
| MACD | 1.82 | -0.02 |
| Stochastic Oscillator | 80.50 | 21.05 |
Limbach Holdings Inc is a building systems solutions firm that designs, delivers, and maintains mechanical (heating, ventilation, and air conditioning), electrical, plumbing, and controls (MEPC) systems. The Company partners with owners and operators of facilities across healthcare, industrial and manufacturing, data centers, life sciences, higher education, and cultural and entertainment markets. It operates through two segments: Owner Direct Relationships (ODR), which generates maximum revenue and includes owner direct projects, maintenance, and service on MEPC systems; and General Contractor Relationships (GCR), which manages new construction or renovation projects involving MEPC systems awarded by general contractors or construction managers.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.